Table 2.
The Clinical and Pathological Information of EGFR+ Patients
| Clinical Factors | All (N=48) | PFS (0–6 Months, N=13) | PFS (7–12 Months, N=19) | PFS (>13 Months, N=16) | P |
|---|---|---|---|---|---|
| Gender, N (%) | 0.599 | ||||
| Male | 19 | 5 | 11 | 3 | |
| Female | 29 | 8 | 8 | 13 | |
| Age, N (%) | 0.060 | ||||
| <65 | 22 | 5 | 9 | 8 | |
| ≥65 | 26 | 8 | 10 | 8 | |
| EGFR baseline | 0.286 | ||||
| Exon 19 (19del) | 21 | 4 | 4 | 8 | |
| Exon 20 (S768I) | 1 | 1 | 1 | 0 | |
| Exon 21 (I858R) | 25 | 7 | 7 | 11 | |
| Exon 21 (L861Q) | 1 | 1 | 1 | 0 | |
| Drug types | 0.085 | ||||
| I-TKI | 38 | 12 | 15 | 11 | |
| II -TKI | 1 | 1 | 0 | 0 | |
| I+III TKI | 9 | 0 | 4 | 5 |
Abbreviations: PFS, progression-free survival; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; I-TKI, Gefitinibor Icotinib; II-TKI, Afatinib; I + III TKI, Gefitinib + Osimertinib.